CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis
In conclusion, we proved that some of the CD19 isoforms contributing to CART-19 escape already preexist at diagnosis and could evolve as a dominant clone during CART-19 therapy suggesting the application of combined treatment approaches.
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Clinical Study Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Allergy & Immunology | Cancer | Cancer & Oncology | Childhood Cancer | Children | Immunotherapy | Leukemia | Study